![NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months](https://pbs.twimg.com/media/FJf6WueVIAMWHvU.jpg)
NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months
![Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum](https://discourse.datamethods.org/uploads/default/original/2X/7/75bb0160b856873819cdcefe4dc6072ed7ef267c.png)
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
![Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-022-01845-z/MediaObjects/41416_2022_1845_Fig3_HTML.png)
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
![Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram](https://www.researchgate.net/publication/44901947/figure/fig1/AS:601654286118955@1520456968641/Survival-curves-A-Overall-survival-median-182-months-B-PS-of-zero-versus-one-or.png)
Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram
![Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram](https://www.researchgate.net/publication/5872888/figure/fig1/AS:601697068015627@1520467168720/Overall-survival-curve-Median-overall-survival-time-was-82-months-The-initial-date-of.png)
Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram
![VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer | 2 Minute Medicine VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer | 2 Minute Medicine](https://www.2minutemedicine.com/wp-content/uploads/2023/08/2MM_08.22.2023_1_Alisha_Lung.jpg)
VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer | 2 Minute Medicine
![Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/41/2/1005/F2.large.jpg)
Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research
![Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience](https://www.mdpi.com/cancers/cancers-14-04897/article_deploy/html/images/cancers-14-04897-g001.png)
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
![Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-022-01637-7/MediaObjects/41375_2022_1637_Fig1_HTML.png)
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia
![NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X](https://pbs.twimg.com/media/CPyBkyOUEAEiJyZ.png)
NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X
![Cureus | A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience | Article Cureus | A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience | Article](https://assets.cureus.com/uploads/figure/file/712037/article_river_8527a120347c11eeba7b99da61fa83a2-figure-1a-resized.png)
Cureus | A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience | Article
![Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of](https://ars.els-cdn.com/content/image/1-s2.0-S0959804914008727-fx6.jpg)
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
![Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with](https://mma.prnewswire.com/media/584686/Overall_Survival_Pancreas_Graph_Infographic.jpg?w=200)
Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with
![Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population](https://www.mdpi.com/biology/biology-10-00890/article_deploy/html/images/biology-10-00890-g001.png)
Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
![Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma | International Journal of Spine Surgery Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma | International Journal of Spine Surgery](https://www.ijssurgery.com/content/ijss/14/6/982/F2.large.jpg)